Progression-dependent transport heterogeneity of breast cancer liver metastases as a factor in therapeutic resistance

Image processing with ImageJ

Michael D. Abràmoff, Paulo Magalhães, Sunanda J. Ram · Data Archiving and Networked Services (DANS) · 2004 · 11.9K citations · Full text

Arts, Computer Science, Biomedical Imaging +16

Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer

E O’Brien, Nely Wigler, Moshe Inbar et al. · Annals of Oncology · 2004 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +17

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

Medicine, Oncology, Pharmacology +16

Tumor Vascular Permeability, Accumulation, and Penetration of Macromolecular Drug Carriers

Matthew R. Dreher, Wenge Liu, Charles R. Michelich et al. · JNCI Journal of the National Cancer Institute · 2006 · 923 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Functional precision cancer medicine—moving beyond pure genomics

Anthony Letai · Nature Medicine · 2017 · 365 citations

Medicine, Cancer Biology, Oncology +14